Predictors of Long-Term Response With Pazopanib in Patients With Advanced Renal-Cell Carcinoma.

@article{Park2018PredictorsOL,
  title={Predictors of Long-Term Response With Pazopanib in Patients With Advanced Renal-Cell Carcinoma.},
  author={Jinhee Park and Xiaolong Jiao and Sameer R Ghate and Thomas W Wilson and Qasim I Ahmad and Nicholas John Vogelzang},
  journal={Clinical genitourinary cancer},
  year={2018},
  volume={16 4},
  pages={
          293-297
        }
}
BACKGROUND Pazopanib is among the current standards of care for first-line treatment of patients with unresectable advanced renal-cell carcinoma (aRCC) or metastatic renal-cell carcinoma. This real-world study aimed to characterize those with long-term response to pazopanib in the treatment of aRCC in a community oncology setting, and to identify predictors… CONTINUE READING